MedPath

Venlafaxine

Generic Name
Venlafaxine
Brand Names
Effexor
Drug Type
Small Molecule
Chemical Formula
C17H27NO2
CAS Number
93413-69-5
Unique Ingredient Identifier
GRZ5RCB1QG
Background

Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997.

Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD). Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches, for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).

Indication

Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.

Associated Conditions
Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
Associated Therapies
-

Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression

Completed
Conditions
Depressive Episode
Interventions
First Posted Date
2017-04-24
Last Posted Date
2018-07-11
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
105
Registration Number
NCT03126188
Locations
🇮🇳

Dept of Psychiatry, Aiims, Bhubaneswar, Bhubaneswar, Odisha, India

Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)

Completed
Conditions
Depression/Depressed State
Interventions
First Posted Date
2016-11-08
Last Posted Date
2023-05-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
1408
Registration Number
NCT02958527

CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia

Not Applicable
Completed
Conditions
Depression
Mild Cognitive Impairment
Anxiety
Interventions
Drug: Sertraline
Drug: Venlafaxine
Other: CBT/Psychological Therapy
Other: Psychiatric Consultation
Other: Lifestyle Intervention Resources
First Posted Date
2016-11-04
Last Posted Date
2021-01-07
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
145
Registration Number
NCT02955719
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea

Phase 4
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
Drug: Venlafaxine
First Posted Date
2016-03-21
Last Posted Date
2020-04-17
Lead Sponsor
University of California, San Diego
Target Recruit Count
20
Registration Number
NCT02714400
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Not Applicable
Completed
Conditions
Depression
Posttraumatic Stress Disorder
Mild Cognitive Impairment
Alcohol-Related Disorders
Substance-Related Disorders
Wounds and Injury
Suicidal Ideation
Brain Injuries
Quality of Life
Chronic Disease
Interventions
First Posted Date
2016-01-14
Last Posted Date
2021-07-02
Lead Sponsor
University of Washington
Target Recruit Count
635
Registration Number
NCT02655354
Locations
🇺🇸

Jacobi Medical Center, Bronx, New York, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Honor Health, Scottsdale, Arizona, United States

and more 21 locations

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2015-12-22
Last Posted Date
2021-01-27
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
54
Registration Number
NCT02637193
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome

Phase 1
Completed
Conditions
Fibromyalgia
Interventions
First Posted Date
2015-05-22
Last Posted Date
2015-05-22
Lead Sponsor
Mansoura University
Target Recruit Count
75
Registration Number
NCT02451475

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine

Phase 4
Completed
Conditions
Vestibular Migraine
Interventions
First Posted Date
2015-01-30
Last Posted Date
2015-01-30
Lead Sponsor
Haseki Training and Research Hospital
Target Recruit Count
73
Registration Number
NCT02350985
Locations
🇹🇷

Haseki Training and Research Hospital, Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath